RxDoctor Payments Data

Robert Grigg, PA

Physician Assistant · Chico, CANPI 1407371941

Payments from drug & device makers

$5,579in general payments, 2019–2025

Across 266 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$772
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$475
  • AstraZeneca$434
  • Amgen$389
  • Bayer$223
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$4,90188%
  • Education$67812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,579 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$275,761
Medicare patients
498
Services billed
20,634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin75$118,989
MounjaroTirzepatide73$102,101
OzempicSemaglutide78$83,231
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$56,385
EliquisApixaban38$47,384
Repatha SureclickEvolocumab50$45,090
RybelsusSemaglutide24$33,202
JanuviaSitagliptin Phosphate19$19,755
KerendiaFinerenone16$16,538
TrulicityDulaglutide12$13,523
MyrbetriqMirabegron13$13,378
BelsomraSuvorexant30$12,915
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen421$9,413
Breo ElliptaFluticasone/Vilanterol14$9,062
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$7,919

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$140$118,98975 claims
Novo NordiskOzempic, Rybelsus$1,246$116,433102 claims
Lilly USA, LLCMounjaro, Trulicity$189$115,62485 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$185$67,92381 claims
PfizerEliquis$197$47,38438 claims
MerckJanuvia, Belsomra$167$32,67049 claims
BayerKerendia$223$16,53816 claims
AbbVieSynthroid$772$2,70151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Chico

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →